The new Xenium In Situ platform enables high-throughput subcellular mapping of 100s of RNA targets in a single tissue section, revealing new insights into cellular structure and function. The Xenium ...

PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently ...

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...

PLEASANTON, Calif., Dec. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the first commercial ...

Picture this: you’re a researcher investigating the complex tumor environment of ductal carcinoma in situ (DCIS). Frustratingly, despite decades of technological advancements, why some DCIS cases ...

Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions ...

ROCKVILLE, Md., Sept. 12, 2023 /PRNewswire/ -- Multiomics CRO Psomagen is thrilled to announce the launch of Spatial Biology services for 10X Genomics Xenium™. This platform is reshaping spatial ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...

We combine advanced technologies such as spatial transcriptomics, multiplexed imaging, and in situ sequencing to map cellular components in their native tissue context. Obtain high-resolution data ...